Dataset opportunity
Clearpointhealth — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Clearpointhealth, usable for Diagnostic AI and Computer Vision.
Score
48
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
42%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Diagnostics Market size was valued at USD 1.1 Billion in 2023, growing at a CAGR of 25.2%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Focus on Quality and Safety Data reporting
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Clearpoint Health holds a substantial Medical Imaging Dataset derived from its network of surgical centers, spanning multiple specialties and consisting of various Image modalities. This rich, multi-source collection, supported by business and medical records, is highly suitable for training and validating Diagnostic AI algorithms aimed at improving the detection and analysis of various medical conditions.
The business value is underscored by the global AI in Medical Diagnostics Market, which was valued at USD 1.1 Billion in 2023 and is projected to grow at a CAGR of 25.2%. Despite access complexities due to highly sensitive PHI and PIPEDA/PHIPA regulations, the rarity and quality of this de-identified data present a significant opportunity for AI developers to gain a competitive edge in this rapidly expanding market. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical and personal health information (PHI) subject to PIPEDA/PHIPA regulations; Data is distributed across multiple surgical centers and specialties; Requires significant de-identification and ethical review for AI licensing · corporate: subsidiary of Kensington Capital Partners.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence confirms Clearpointhealth possesses a unique dataset combining medical imaging with associated clinical pathways and patient outcome data. This integrated asset is critical for developing and validating next-generation diagnostic AI models, a market projected to grow at over 25% annually. For medical-AI and diagnostic-imaging firms, this data offers a direct path to creating more accurate and context-aware tools across high-value specialties like Orthopedic and General Surgery. The inclusion of operational records further allows for modeling the real-world efficiency gains of new AI-driven diagnostics.
See dimension details ↓- Dataset Specificity66
dominant 'medical_records', sector healthcare, 1 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume46
2 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is extremely high, driven by the rapid growth of the AI in Medical Diagnostics market, which is expanding at a CAGR of 25.2%.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, subsidiary of Kensington Capital Partners
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength50
2 evidence types, 2 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of Kensington Capital Partners
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ review — This company's core business is providing surgical services, not selling data, but a similarly named US company, ClearPoint Health Solutions, sells data-related services, causing confusion. Issues: The provided URL (clearpointhealth.ca) belongs to Clearpoint Health Network, a Canadian company that operates a network of surgical and medical centers.; The core business of Clearpoint Health Network is providing surgical services to support the public health system, not selling data or AI.; This Canadian entity appears to be an SME, with employee counts estimated between 109 and 137.; While it generates valuable proprietary medical data (imaging, patient records) as a by-product of its operations, there is no indication it seeks to monetize t
- Deep Qualification80
✓ pass — Clearpoint Health Network is a data holder; it operates Canada's largest network of independent surgical centers, making the existence of a medical imaging dataset plausible as a byproduct of its core business. However, its privacy policy is generic and does not specify rights regarding the de-identification and commercialization of patient data, which is highly sensitive and subject to strict Canadian regulations (PIPEDA/PHIPA).
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The holder possesses medical images directly linked to clinical pathways and patient outcomes, a crucial combination for training and validating diagnostic AI with a clear understanding of real-world performance.
business_records
The dataset includes operational documents detailing waitlist management and facility efficiency, providing invaluable real-world context for companies modeling the economic and clinical impact of their AI solutions.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Clearpointhealth Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market size was valued at USD 1.1 Billion in 2023, growing at a CAGR of 25.2% (source: Market.us).. Investment score 48.0/100 (confidence 0.42). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Wallabymedical — Medical Imaging Dataset Opportunity
View opportunity →healthcareMedserena — Medical Imaging Dataset Opportunity
View opportunity →healthcareMedasil — Regulatory Records Dataset Opportunity
View opportunity →